220 related articles for article (PubMed ID: 32992152)
1. Head and neck cancer patient-derived xenograft models - A systematic review.
Schuch LF; Silveira FM; Wagner VP; Borgato GB; Rocha GZ; Castilho RM; Vargas PA; Martins MD
Crit Rev Oncol Hematol; 2020 Nov; 155():103087. PubMed ID: 32992152
[TBL] [Abstract][Full Text] [Related]
2. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers.
Peng S; Creighton CJ; Zhang Y; Sen B; Mazumdar T; Myers JN; Lai SY; Woolfson A; Lorenzi MV; Bell D; Williams MD; Johnson FM
J Transl Med; 2013 Aug; 11():198. PubMed ID: 23981300
[TBL] [Abstract][Full Text] [Related]
3. Patient derived xenografts as models for head and neck cancer.
Nitschinsk K; Idris A; McMillan N
Cancer Lett; 2018 Oct; 434():114-119. PubMed ID: 30031118
[TBL] [Abstract][Full Text] [Related]
4. Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review.
Tanaka T; Nishie R; Ueda S; Miyamoto S; Hashida S; Konishi H; Terada S; Kogata Y; Sasaki H; Tsunetoh S; Taniguchi K; Komura K; Ohmichi M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502278
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived xenograft (PDX) tumors increase growth rate with time.
Pearson AT; Finkel KA; Warner KA; Nör F; Tice D; Martins MD; Jackson TL; Nör JE
Oncotarget; 2016 Feb; 7(7):7993-8005. PubMed ID: 26783960
[TBL] [Abstract][Full Text] [Related]
6. IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence.
Finkel KA; Warner KA; Kerk S; Bradford CR; McLean SA; Prince ME; Zhong H; Hurt EM; Hollingsworth RE; Wicha MS; Tice DA; Nör JE
Neoplasia; 2016 May; 18(5):273-281. PubMed ID: 27237319
[TBL] [Abstract][Full Text] [Related]
7. Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma.
Wu M; Liu Y; Zhao Y; Zhang Y; Huang L; Du Q; Zhang T; Zhong Z; Luo H; Xiao K
J Vis Exp; 2023 Jun; (196):. PubMed ID: 37335092
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a patient-derived xenograft model and cell line of malignant transformation of mature cystic teratoma of the ovary.
Tamauchi S; Suzuki S; Xuboya C; Yoshihara M; Yoshida K; Ikeda Y; Yoshikawa N; Kajiyama H; Kikkawa F
J Obstet Gynaecol Res; 2021 Feb; 47(2):713-719. PubMed ID: 33300248
[TBL] [Abstract][Full Text] [Related]
9. Targeting of Head and Neck Cancer by Radioiodinated CLR1404 in Murine Xenograft Tumor Models with Partial Volume Corrected Theranostic Dosimetry.
Marsh IR; Li C; Grudzinski J; Jeffery J; Longhurst C; Adam DP; Hernandez R; Weichert JP; Harari PM; Bednarz BP
Cancer Biother Radiopharm; 2023 Sep; 38(7):458-467. PubMed ID: 37022739
[No Abstract] [Full Text] [Related]
10. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer.
Yu CC; Tsai LL; Wang ML; Yu CH; Lo WL; Chang YC; Chiou GY; Chou MY; Chiou SH
Cancer Res; 2013 Jun; 73(11):3425-40. PubMed ID: 23548270
[TBL] [Abstract][Full Text] [Related]
11. [Application and development of patient-derived tumor xenograft model in translational medicine of tumor].
Wang Z; Zhu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 May; 20(5):596-600. PubMed ID: 28534338
[TBL] [Abstract][Full Text] [Related]
12. Patient-Derived Bladder Cancer Xenografts.
Bernardo C; Santos LL
Methods Mol Biol; 2018; 1655():169-175. PubMed ID: 28889386
[TBL] [Abstract][Full Text] [Related]
13. Xenografts derived from patients with head and neck cancer recapitulate patient tumour properties.
Makita H; Endo K; Kasahara Y; Nakata A; Moriyama-Kita M; Ishikawa K; Ueno T; Nakanishi Y; Kondo S; Wakisaka N; Gotoh N; Yoshizaki T
Oncol Lett; 2021 May; 21(5):385. PubMed ID: 33777208
[TBL] [Abstract][Full Text] [Related]
14. Establishment and characterization of a non-gestational choriocarcinoma patient-derived xenograft model.
Oda Y; Niimi K; Yoshida K; Tamauchi S; Yokoi A; Yasui Y; Nishiko Y; Shibata M; Shimizu Y; Yoshihara M; Ikeda Y; Yoshikawa N; Nishino K; Yamamoto E; Kajiyama H
BMC Cancer; 2023 Nov; 23(1):1103. PubMed ID: 37957624
[TBL] [Abstract][Full Text] [Related]
15. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
Roh JL; Park JY; Kim EH; Jang HJ
Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
[TBL] [Abstract][Full Text] [Related]
16. A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option.
Klinghammer K; Raguse JD; Plath T; Albers AE; Joehrens K; Zakarneh A; Brzezicha B; Wulf-Goldenberg A; Keilholz U; Hoffmann J; Fichtner I
Int J Cancer; 2015 Jun; 136(12):2940-8. PubMed ID: 25404014
[TBL] [Abstract][Full Text] [Related]
17. [Knowledge and practice of patient-derived xenograft models in leukemia].
Kato I
Rinsho Ketsueki; 2022; 63(9):1335-1343. PubMed ID: 36198560
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of patient-derived head and neck cancer models from surgical specimens and endoscopic biopsies.
Strüder D; Momper T; Irmscher N; Krause M; Liese J; Schraven S; Zimpfer A; Zonnur S; Burmeister AS; Schneider B; Frerich B; Mlynski R; Große-Thie C; Junghanss C; Maletzki C
J Exp Clin Cancer Res; 2021 Aug; 40(1):246. PubMed ID: 34362423
[TBL] [Abstract][Full Text] [Related]
19. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
[TBL] [Abstract][Full Text] [Related]
20. Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models.
Prasetyanti PR; van Hooff SR; van Herwaarden T; de Vries N; Kalloe K; Rodermond H; van Leersum R; de Jong JH; Franitza M; Nürnberg P; Todaro M; Stassi G; Medema JP
Int J Cancer; 2019 Jan; 144(2):366-371. PubMed ID: 30151914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
